Page 215 - 2019_04-Haematologica-web

Severity of chronic GvHD after alternative donor HCT
host disease. Blood. 2013;121(25):5098-
5103.
26. Detrait MY, Morisset S, Peffault de Latour R,
et al. Pre-transplantation risk factors to develop sclerotic chronic GvHD after allo- geneic HSCT: a multicenter retrospective study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM- TC). Bone Marrow Transplant. 2015;50(2): 253-258.
27. Newell LF, Flowers ME, Gooley TA, et al. Characteristics of chronic GVHD after cord blood transplantation. Bone Marrow Transplant. 2013;48(10):1285-1290.
28. Flowers MED, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host dis- ease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a random- ized trial. Blood. 2002;100(2):415-419.
29. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chron- ic graft-versus-host disease. Blood. 2004;104(12):3501-3506.
30. Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood. 2009;114(3):702-708.
31. Hamilton JG, Wu LM, Austin JE, et al. Economic survivorship stress is associated with poor health-related quality of life among distressed survivors of hematopoiet- ic stem cell transplantation. Psychooncology. 2013;22(4):911-921.
36. Kanda J, Nakasone H, Atsuta Y, et al. Risk factors and organ involvement of chronic GVHD in Japan. Bone Marrow Transplant. 2014;49(2):228-235.
37. Lazaryan A, Weisdorf DJ, DeFor T, et al. Risk factors for acute and chronic graft-ver- sus-host disease after allogeneic hematopoi- etic cell transplantation with umbilical cord blood and matched sibling donors. Biol Blood Marrow Transplant. 2016;22(1):134-
32. Storb R, Prentice RL, Sullivan KM, et al.
Predictive factors in chronic graft-versus-
host disease in patients with aplastic anemia
treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 140.
1983;98(4):461-466.
33. Carlens S, Ringden O, Remberger M, et al.
Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22(8):755-761.
34. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75(12): 2459-2464.
35. Flowers MED, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214-3219.
38. Lee SJ, Klein J, Haagenson M, et al. High-res- olution donor-recipient HLA matching con- tributes to the success of unrelated donor marrow transplantation. Blood. 2007;110 (13):4576-4583.
39. Socie G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-ver- sus-host disease prophylaxis with or with- out anti-T-cell globulin ATG-Fresenius. Blood. 2011;117(23):6375-6382.
40. Uhm J, Hamad N, Shin EM, et al. Incidence, risk factors, and long-term outcomes of scle- rotic graft-versus-host disease after allogene- ic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(11): 1751-1757.
haematologica | 2019; 104(4)
843